Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Gyre Therapeutics ( (GYRE) ) is now available.
On May 22, 2025, Gyre Therapeutics, Inc. announced an underwriting agreement with Jefferies LLC to issue and sell 2,222,222 shares of common stock at $9.00 per share, with an option for underwriters to purchase an additional 333,333 shares. The company expects to raise approximately $18.5 million, which will be used to fund a Phase 2 clinical trial of F351 in the United States, as well as for research, development, and general corporate purposes. The offering is set to close on May 27, 2025, subject to customary conditions.
The most recent analyst rating on (GYRE) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Gyre Therapeutics stock, see the GYRE Stock Forecast page.
Spark’s Take on GYRE Stock
According to Spark, TipRanks’ AI Analyst, GYRE is a Neutral.
The overall stock score for Gyre Therapeutics is driven primarily by recent positive corporate events, which highlight significant strategic progress and potential market impact. However, this is offset by financial performance challenges, particularly in cash flow and valuation concerns due to a high P/E ratio. Technical analysis suggests some positive momentum, but these factors are secondary to the strategic developments.
To see Spark’s full report on GYRE stock, click here.
More about Gyre Therapeutics
Gyre Therapeutics, Inc. operates in the biotechnology industry, focusing on the development of therapeutics. The company is primarily engaged in advancing clinical trials and research in metabolic dysfunction-associated steatohepatitis-associated liver fibrosis.
Average Trading Volume: 160,088
Technical Sentiment Signal: Hold
Current Market Cap: $987.6M
See more insights into GYRE stock on TipRanks’ Stock Analysis page.